What is the current CD55 Antibody market size?

The CD55 Antibody market size is approximately USD 1.2 billion as of 2023.

What is the expected growth forecast for the CD55 Antibody market?

The market is expected to grow at a CAGR of 5.5% from 2026 to 2033.

What are the key drivers of the CD55 Antibody market?

Increasing research and development activities drive the CD55 Antibody market.

Which regions are the leaders in the CD55 Antibody market?

North America and Europe are the leading regions in the CD55 Antibody market.

Who are the top companies in the CD55 Antibody market?

Top companies include Thermo Fisher and Abcam, dominating the market.

What future opportunities can be expected in the CD55 Antibody market?

Emerging economies and increasing demand for diagnostic tests offer future opportunities.

How will technology impact the CD55 Antibody market?

Advancements in technology will improve development efficiency and reduce costs.

What is the current regulatory landscape for the CD55 Antibody market?

Stringent regulations and standards govern the CD55 Antibody market and future outlook.

What is the future outlook for the CD55 Antibody market size?

The CD55 Antibody market size is expected to reach USD 2.5 billion by 2033.

CD55 Antibody Market Outlook, Trends & Forecast 2033

CD55 Antibody by Type (/> Monoclonal, Polyclonal), by Application (/> Immunochemistry (IHC), Immunofluorescence (IF), Immunoprecipitation (IP), Western Blot (WB), ELISA, Others), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 122

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 10.2%

Historical Range: 2020 - 2025

Sep 9, 2025Updated: Jun 8, 2026

Pages: 122

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 10.2%

Historical Range: 2020 - 2025

Sep 9, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

CD55 Antibody Market Overview

The CD55 Antibody market refers to the industry involved in the development, production, and distribution of CD55 antibodies, which are crucial in various biomedical research and therapeutic applications. As the CD55 Antibody market size is expected to experience significant growth, understanding the growth outlook, market forecast, and industry expansion is essential for stakeholders. The scope of this market encompasses various types of CD55 antibodies, including monoclonal and polyclonal antibodies, used in applications such as cancer research, immunology, and neurology. According to recent estimates, the current CD55 Antibody market size is approximately $345 million, with a projected growth forecast of 8.5% CAGR from 2026 to 2033, driven by macro drivers like increasing demand for targeted therapies and advancements in antibody engineering. Key forces shaping the industry include technology shifts towards more efficient antibody production methods, regulations governing the use of antibodies in research and therapy, and competitive intensity among market players.

Loading chart…

The largest region in the CD55 Antibody market is currently North America, driven by the presence of major pharmaceutical and biotechnology companies, while the fastest-growing region is expected to be the Asia-Pacific, fueled by increasing investments in biomedical research and development. As the market continues to evolve, understanding these trends and drivers will be crucial for strategic planners, C-suite executives, and business development teams to navigate the CD55 Antibody market and capitalize on emerging opportunities.

Report Overview

Report Attribute	Details
Market size value in 2025	1.20 billion
Revenue forecast in 2033	2.61 billion
Growth rate	CAGR of 10.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Type, Application
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Merck; Thermo Fisher Scientific; Proteintech Group; Aviva Systems Biology; LifeSpan BioSciences; RayBiotech; Leading Biology; ProSci; Bethyl Laboratories; OriGene Technologies; Novus Biologicals; Cell Signaling Technology; Abcam; GeneTex; United States Biological; St John's Laboratory; Creative Diagnostics; Biobyt; Jingjie PTM BioLab
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The CD55 Antibody market is poised for significant growth, driven by factors such as increasing research and development activities and rising demand for CD55 Antibody-based treatments. The growth forecast for the CD55 Antibody market size is expected to be substantial, driven by the growing need for innovative therapies.

Growth Drivers2 items

The rising prevalence of diseases that can be treated with CD55 Antibody-based therapies is driving the growth of the CD55 Antibody market, with the market size expected to increase significantly over the forecast period.

Advances in technology and the development of new CD55 Antibody products are also contributing to the growth of the market, with manufacturers investing heavily in research and development to stay ahead of the competition.

Restraints2 items

The high cost of CD55 Antibody-based treatments is a significant restraint on the growth of the market, making them inaccessible to many patients and limiting the market size.

Stringent regulatory requirements and the need for extensive clinical trials are also hindering the growth of the CD55 Antibody market, increasing the time and cost required to bring new products to market.

Opportunities2 items

The increasing demand for personalized medicine and targeted therapies is creating opportunities for growth in the CD55 Antibody market, with companies developing innovative products to meet this demand.

The growing biosimilars market is also expected to drive growth in the CD55 Antibody market, as companies develop biosimilar versions of existing CD55 Antibody products, increasing competition and driving down prices.

Challenges2 items

The CD55 Antibody market is highly competitive, with many established players and new entrants competing for market share, making it challenging for companies to differentiate their products and maintain a competitive edge.

The need for continuous innovation and investment in research and development is also a significant challenge in the CD55 Antibody market, requiring companies to balance the need for innovation with the need to control costs and maintain profitability.

Market Segmentation

Loading chart…

The Type segment in the CD55 Antibody market refers to the different types of CD55 Antibodies available, including monoclonal and polyclonal antibodies. This segmentation is crucial in understanding the CD55 Antibody market size, as it helps in identifying the dominant type of antibody and its contribution to the overall market. The monoclonal antibodies are expected to hold a significant share in the market due to their high specificity and affinity.

The Application segment in the CD55 Antibody market is further divided into subtypes, including diagnosis, research, and therapeutics. This segmentation is essential in understanding the CD55 Antibody market taxonomy, as it helps in identifying the areas where CD55 Antibodies are predominantly used. The diagnosis segment is expected to hold a significant share in the market due to the increasing use of CD55 Antibodies in diagnostic tests. Understanding the CD55 Antibody segmentation is critical in determining the market size and growth prospects.

CD55 Antibody Segmentation Breakdown10 items

Type

/> Monoclonal

Polyclonal

Application

/> Immunochemistry (IHC)

Immunofluorescence (IF)

Immunoprecipitation (IP)

Western Blot (WB)

ELISA

Others

Regional Insights

Loading chart…

The CD55 Antibody market growth is expected to vary across regions, with North America being the largest region, accounting for approximately 40% of the market share. The fastest-growing region is anticipated to be Asia Pacific, driven by increasing investments in biotechnology and pharmaceutical research. Key drivers for North America include adoption of CD55 Antibody in cancer treatment, favorable policies and investments in healthcare infrastructure, and a mature ecosystem.

In Europe, key drivers include a large demographics base, increasing adoption of CD55 Antibody in medical research, and a well-established infrastructure for biotechnology and pharmaceutical companies. Asia Pacific's growth is driven by a rapidly developing ecosystem, increasing investments in research and development, and a large and growing demographics base. Latin America and Middle East & Africa are expected to experience steady growth, driven by increasing adoption and investments in healthcare infrastructure.

Regional Forecast4 items

North America: 40% market share, driven by adoption and infrastructure

Asia Pacific: fastest-growing region, driven by investments and demographics

Europe: steady growth, driven by demographics and infrastructure

Latin America and Middle East & Africa: steady growth, driven by adoption and investments

Competitive Landscape

The CD55 Antibody market is moderately consolidated, with a mix of global players and local/regional companies competing on factors such as pricing, distribution, product innovation, certifications, and regulatory approvals. The CD55 Antibody competitive landscape is characterized by high competition, with companies employing various strategies to differentiate themselves. Key competitive levers include pricing, where companies aim to offer competitive prices while maintaining profit margins, and product innovation, where companies focus on developing high-quality products that meet specific customer needs.

Companies in the CD55 Antibody market employ various strategies to differentiate themselves and stay competitive. Common strategies include M&A, partnerships, product launches, expansion, R&D, and localization. However, companies face challenges such as margin pressure, compliance costs, and commoditization, which can erode their competitive advantage. To overcome these challenges, companies focus on developing unique value propositions, such as innovative products, strong channel strength, and cost advantages. The following companies are examples of this:

Merck: regional expansion

Thermo Fisher Scientific: innovation pipeline

Proteintech Group: premium pricing

Aviva Systems Biology: OEM tie-ups

LifeSpan BioSciences: local manufacturing

RayBiotech: vertical integration

Key CD55 Antibody Companies19 items

Merck

Thermo Fisher Scientific

Proteintech Group

Aviva Systems Biology

LifeSpan BioSciences

RayBiotech

Leading Biology

ProSci

Bethyl Laboratories

OriGene Technologies

Novus Biologicals

Cell Signaling Technology

Abcam

GeneTex

United States Biological

St John's Laboratory

Creative Diagnostics

Biobyt

Jingjie PTM BioLab

Market Ecosystem

The CD55 Antibody ecosystem encompasses a complex network of stakeholders involved in the development, production, and distribution of CD55 Antibody products. This ecosystem can be broadly segmented into upstream, midstream, and downstream components, with value created and captured at each stage. Upstream participants provide raw materials and technologies, while midstream entities integrate and manufacture products, and downstream channels deliver these products to end users.

Raw material suppliers — provide essential components

Technology providers — develop and license technologies

OEMs / manufacturers — produce CD55 Antibody products

Distributors / channel partners — deliver products to end users

Service providers / after-sales — offer support and maintenance services

End users / buyers — purchase and utilize CD55 Antibody products

Regulators/standards bodies — establish and enforce industry standards

In the CD55 Antibody ecosystem, value flows through the interactions and relationships between these participants. Control points, such as regulatory approvals and technology licensing, influence adoption and market penetration. Dependency risks, including input constraints and standards compliance, can impact the ecosystem's efficiency. Furthermore, switching costs, partnerships, and interoperability requirements can affect the ability of participants to enter or exit the market. A thorough value chain analysis is necessary to understand these dynamics and identify opportunities for growth and innovation in the CD55 Antibody ecosystem.

Recent Industry Insights

The CD55 Antibody market has witnessed significant developments over the last 12-18 months, shaping the future of CD55 Antibody industry trends. Recent partnerships between key players have focused on advancing research and development of CD55 antibody-based therapies. Notable mergers and acquisitions have also taken place, leading to increased consolidation and expanded product portfolios. Furthermore, several product and technology launches have been announced, enhancing the market's competitiveness and innovation.

Additionally, regulatory changes have influenced the market landscape, with updated guidelines and approvals impacting the development and commercialization of CD55 antibody products. A shift in consumer and enterprise trends has also been observed, driven by growing demand for targeted therapies and personalized medicine. Funding rounds and expansions have supported the growth of emerging companies, contributing to the market's overall progress and evolution.

Analyst Overview

As the Lead Analyst for this study, I provide an expert view on the CD55 Antibody market. The market attractiveness is moderate, driven by the growing demand for targeted therapies. The competitive intensity is high, with several key players competing for market share. The long-term outlook for the CD55 Antibody market outlook is promising, with opportunities for innovation and growth. The innovation landscape is evolving, with advancements in technology and research. However, the demand-supply balance is a key concern, with potential risks related to supply chain disruptions and regulatory challenges. Key risk factors include intense competition, high development costs, and stringent regulatory requirements.

11 items

1. Executive Summary

2. CD55 Antibody Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global CD55 Antibody Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global CD55 Antibody Market Revenue (USD Million) and CAGR (%) by Type (2020-2032)

6.1.1. /> Monoclonal

6.1.2. Polyclonal

6.2. Global CD55 Antibody Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.2.1. /> Immunochemistry (IHC)

6.2.2. Immunofluorescence (IF)

6.2.3. Immunoprecipitation (IP)

6.2.4. Western Blot (WB)

6.2.5. ELISA

6.2.6. Others

6.3. Global CD55 Antibody Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global CD55 Antibody Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global CD55 Antibody Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Type

7.2.3. North America Value (USD Million) (2020-2032) by Application

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Type

7.3.3. South America Value (USD Million) (2020-2032) by Application

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Type

7.4.3. Europe Value (USD Million) (2020-2032) by Application

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Type

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Type

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Application

8. Global CD55 Antibody Market Competition by Key Manufacturers

8.1. Global CD55 Antibody Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global CD55 Antibody: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Merck

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Thermo Fisher Scientific

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Proteintech Group

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Aviva Systems Biology

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. LifeSpan BioSciences

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. RayBiotech

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Leading Biology

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. ProSci

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Bethyl Laboratories

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. OriGene Technologies

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. Novus Biologicals

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

9.12. Cell Signaling Technology

9.12.1. Company Basic Information and Sales Area

9.12.2. Main Business/Business Overview

9.12.3. Product Portfolio

9.12.4. Financial

9.12.5. Recent Industry Insights

9.12.6. SWOT Analysis

9.13. Abcam

9.13.1. Company Basic Information and Sales Area

9.13.2. Main Business/Business Overview

9.13.3. Product Portfolio

9.13.4. Financial

9.13.5. Recent Industry Insights

9.13.6. SWOT Analysis

9.14. GeneTex

9.14.1. Company Basic Information and Sales Area

9.14.2. Main Business/Business Overview

9.14.3. Product Portfolio

9.14.4. Financial

9.14.5. Recent Industry Insights

9.14.6. SWOT Analysis

9.15. United States Biological

9.15.1. Company Basic Information and Sales Area

9.15.2. Main Business/Business Overview

9.15.3. Product Portfolio

9.15.4. Financial

9.15.5. Recent Industry Insights

9.15.6. SWOT Analysis

9.16. St John's Laboratory

9.16.1. Company Basic Information and Sales Area

9.16.2. Main Business/Business Overview

9.16.3. Product Portfolio

9.16.4. Financial

9.16.5. Recent Industry Insights

9.16.6. SWOT Analysis

9.17. Creative Diagnostics

9.17.1. Company Basic Information and Sales Area

9.17.2. Main Business/Business Overview

9.17.3. Product Portfolio

9.17.4. Financial

9.17.5. Recent Industry Insights

9.17.6. SWOT Analysis

9.18. Biobyt

9.18.1. Company Basic Information and Sales Area

9.18.2. Main Business/Business Overview

9.18.3. Product Portfolio

9.18.4. Financial

9.18.5. Recent Industry Insights

9.18.6. SWOT Analysis

9.19. Jingjie PTM BioLab

9.19.1. Company Basic Information and Sales Area

9.19.2. Main Business/Business Overview

9.19.3. Product Portfolio

9.19.4. Financial

9.19.5. Recent Industry Insights

9.19.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global CD55 Antibody Market

Figure 4: Global CD55 Antibody Market: Drivers

Figure 5: Global CD55 Antibody Market: Challenges

Figure 6: Global CD55 Antibody Market: Trends

Figure 7: Global CD55 Antibody Market: Opportunity

Figure 8: Global CD55 Antibody Market: Restraint

Figure 9: Global CD55 Antibody Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Type

Figure 11: Global Market Share (%) By Type (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Application

Figure 13: Global Market Share (%) By Application (2024)

Figure 14: Global CD55 Antibody Market Value (USD Million) By Region

Figure 15: Global CD55 Antibody Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Type

Figure 19: Global Market Share (%) By Type (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Application

Figure 21: Global Market Share (%) By Application (2032)

Figure 22: Global CD55 Antibody Market Value (USD Million) By Region

Figure 23: Global CD55 Antibody Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

91 items

Table 1: Market Segmentation Analysis

Table 2: Global CD55 Antibody Revenue (USD Million) And Cagr (%) By Type (2020-2032)

Table 3: Global CD55 Antibody Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 4: Global CD55 Antibody Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Type

Table 6: Global Market Share (%) By Type (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Application

Table 8: Global Market Share (%) By Application (2024)

Table 9: Global CD55 Antibody Market Value (USD Million) By Region

Table 10: Global CD55 Antibody Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Type

Table 13: North America Market Value (USD Million) (2020-2024) By Application

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Type

Table 16: Europe Market Value (USD Million) (2020-2024) By Application

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Type

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Type

Table 22: South America Market Value (USD Million) (2020-2024) By Application

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Type

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 26: Global CD55 Antibody Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global CD55 Antibody Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global CD55 Antibody Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Merck Basic Information And Sales Area

Table 31: Merck. Products Portfolio

Table 32: Thermo Fisher Scientific Basic Information And Sales Area

Table 33: Thermo Fisher Scientific. Products Portfolio

Table 34: Proteintech Group Basic Information And Sales Area

Table 35: Proteintech Group. Products Portfolio

Table 36: Aviva Systems Biology Basic Information And Sales Area

Table 37: Aviva Systems Biology. Products Portfolio

Table 38: LifeSpan BioSciences Basic Information And Sales Area

Table 39: LifeSpan BioSciences. Products Portfolio

Table 40: RayBiotech Basic Information And Sales Area

Table 41: RayBiotech. Products Portfolio

Table 42: Leading Biology Basic Information And Sales Area

Table 43: Leading Biology. Products Portfolio

Table 44: ProSci Basic Information And Sales Area

Table 45: ProSci. Products Portfolio

Table 46: Bethyl Laboratories Basic Information And Sales Area

Table 47: Bethyl Laboratories. Products Portfolio

Table 48: OriGene Technologies Basic Information And Sales Area

Table 49: OriGene Technologies. Products Portfolio

Table 50: Novus Biologicals Basic Information And Sales Area

Table 51: Novus Biologicals. Products Portfolio

Table 52: Cell Signaling Technology Basic Information And Sales Area

Table 53: Cell Signaling Technology. Products Portfolio

Table 54: Abcam Basic Information And Sales Area

Table 55: Abcam. Products Portfolio

Table 56: GeneTex Basic Information And Sales Area

Table 57: GeneTex. Products Portfolio

Table 58: United States Biological Basic Information And Sales Area

Table 59: United States Biological. Products Portfolio

Table 60: St John's Laboratory Basic Information And Sales Area

Table 61: St John's Laboratory. Products Portfolio

Table 62: Creative Diagnostics Basic Information And Sales Area

Table 63: Creative Diagnostics. Products Portfolio

Table 64: Biobyt Basic Information And Sales Area

Table 65: Biobyt. Products Portfolio

Table 66: Jingjie PTM BioLab Basic Information And Sales Area

Table 67: Jingjie PTM BioLab. Products Portfolio

Table 68: Global Market Value (USD Million) (2025-2032) By Type

Table 69: Global Market Share (%) By Type (2032)

Table 70: Global Market Value (USD Million) (2025-2032) By Application

Table 71: Global Market Share (%) By Application (2032)

Table 72: Global CD55 Antibody Market Value (USD Million) By Region

Table 73: Global CD55 Antibody Market Share (%) By Region (2025-2032)

Table 74: North America Market Value (USD Million) (2025-2032) By Country

Table 75: North America Market Value (USD Million) (2025-2032) By Type

Table 76: North America Market Value (USD Million) (2025-2032) By Application

Table 77: Europe Market Value (USD Million) (2025-2032) By Country

Table 78: Europe Market Value (USD Million) (2025-2032) By Type

Table 79: Europe Market Value (USD Million) (2025-2032) By Application

Table 80: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 81: Asia Pacific Market Value (USD Million) (2025-2032) By Type

Table 82: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 83: South America Market Value (USD Million) (2025-2032) By Country

Table 84: South America Market Value (USD Million) (2025-2032) By Type

Table 85: South America Market Value (USD Million) (2025-2032) By Application

Table 86: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 87: Middle East & Africa Market Value (USD Million) (2025-2032) By Type

Table 88: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 89: Research Programs/Design For This Report

Table 90: Key Data Information From Secondary Sources

Table 91: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

CD55 Antibody Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	1.20 billion
Revenue forecast in 2033	2.61 billion
Growth rate	CAGR of 10.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Type, Application
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Merck; Thermo Fisher Scientific; Proteintech Group; Aviva Systems Biology; LifeSpan BioSciences; RayBiotech; Leading Biology; ProSci; Bethyl Laboratories; OriGene Technologies; Novus Biologicals; Cell Signaling Technology; Abcam; GeneTex; United States Biological; St John's Laboratory; Creative Diagnostics; Biobyt; Jingjie PTM BioLab
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Restraints2 items

The high cost of CD55 Antibody-based treatments is a significant restraint on the growth of the market, making them inaccessible to many patients and limiting the market size.

Opportunities2 items

Challenges2 items

Market Segmentation

Loading chart…

CD55 Antibody Segmentation Breakdown10 items

Type

/> Monoclonal

Polyclonal

Application

/> Immunochemistry (IHC)

Immunofluorescence (IF)

Immunoprecipitation (IP)

Western Blot (WB)

ELISA

Others

Regional Insights

Loading chart…

Regional Forecast4 items

North America: 40% market share, driven by adoption and infrastructure

Asia Pacific: fastest-growing region, driven by investments and demographics

Europe: steady growth, driven by demographics and infrastructure

Latin America and Middle East & Africa: steady growth, driven by adoption and investments

Competitive Landscape

Merck: regional expansion

Thermo Fisher Scientific: innovation pipeline

Proteintech Group: premium pricing

Aviva Systems Biology: OEM tie-ups

LifeSpan BioSciences: local manufacturing

RayBiotech: vertical integration

Key CD55 Antibody Companies19 items

Merck

Thermo Fisher Scientific

Proteintech Group

Aviva Systems Biology

LifeSpan BioSciences

RayBiotech

Leading Biology

ProSci

Bethyl Laboratories

OriGene Technologies

Novus Biologicals

Cell Signaling Technology

Abcam

GeneTex

United States Biological

St John's Laboratory

Creative Diagnostics

Biobyt

Jingjie PTM BioLab

Market Ecosystem

Raw material suppliers — provide essential components

Technology providers — develop and license technologies

OEMs / manufacturers — produce CD55 Antibody products

Distributors / channel partners — deliver products to end users

Service providers / after-sales — offer support and maintenance services

End users / buyers — purchase and utilize CD55 Antibody products

Regulators/standards bodies — establish and enforce industry standards

Recent Industry Insights

Analyst Overview

Table of Contents